UNSPSC 51162631: Levopropoxyphene napsilate or levopropoxyphene napsylate

This classification denotes an antitussive agent with the molecular formula C22H29NO2.C10H8O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KK9590R73S, chemically known as benzeneethanol, .alpha.-(2-(dimethylamino)-1-methylethyl)-.alpha.-phenyl-, propanoate (ester), (r-(r*,s*))-, compd. with 2-naphthalenesulfonic acid (1:1), monohydrate, but more generally known as levopropoxyphene napsilate, which bears US NIH Compound Identifier 64736.

European Medicines Agency schedules levopropoxyphene napsilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08486MIG. Most nations, for tariff purposes, schedule levopropoxyphene napsilate under HS 29221980. SMILES: CCC(=O)O[C@@](CC1CCCCC1)(C2CCCCC2)[C@@H](C)CN(C)C.C1CCC2CC(CCC2C1)S(=O)(=O)O.O.

UNSPSC 51162631 Levopropoxyphene napsilate or levopropoxyphene napsylate is a Commodity code that captures state and local procurement of pharmaceutical products, though recent opportunities tagged to this code show limited direct relevance to the specific active ingredient — the recent solicitations map more broadly to naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than levopropoxyphene formulations specifically. State and local issuers purchasing under this code include county health departments and state cooperative purchasing alliances coordinating pharmaceutical procurement across multiple jurisdictions and authorized distributors.

Geographic activity appears concentrated in the Southeast and Upper Midwest, with Seminole County, Florida issuing a competitive bid for naloxone and drug deactivation systems, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issuing an RFP for generic multi-source pharmaceuticals and OTC products spanning participating state and local facilities including Oregon. Seminole County's IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023. MMCAP's RFP S1070000015802, posted January 20, 2026, established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with proposals due March 26, 2026 and awarded vendor agreements effective July 1, 2026; vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two authorized wholesalers, and comply with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.